Genotoxicity, Nerve Damage, Nerve Degeneration, Nerve Injury, Neuroinflammatory Response, Neurotoxicity
Conditions
Keywords
organophosphates, neuroinflammatory biomarkers, metabolomic and proteomic analysis, oxidative stress biomarkers, nerve damage, acute and chronic toxicity, neuroinflammation, inflammatory response, pesticides, acetyl choline esterase enzyme inhibition
Brief summary
The aim of this observational study is to answer the following questions in individuals with acute and chronic exposure to organophosphates. The main questions to be addressed are 1. What are the prognostic values of neuroinflammatory markers? 2. What are the genotoxic effects of organophosphates? 3. what are the changes occurring in the levels of traditional oxidative stress and inflammatory markers?
Detailed description
This is a cross-sectional study that aims to assess the possible prognostic value of markers of neuroinflammation and nerve damage in patients with acute and chronic exposure to organophosphate pesticides by conducting a full proteomic and metabolomic profile. The possible genotoxic effect of common organophosphate pesticides will be studied as well. This will be conducted in parallel to the assessment of traditional markers of inflammation and oxidative stress. The target populations are patients with acute and chronic exposure to organophosphates with a total estimated number of 90 including individuals assigned to the control group with matched age and gender.
Interventions
OTHERexposure to organophosphates
organophosphates are esters of phosphoric acids or Thio phosphoric acids that exist in pesticides, where patients can be chronically or acutely exposed to such compounds.
Sponsors
Alexandria University
Study design
Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* For the control group: healthy individuals without previous exposure to organophosphates, with the specified age limits. * For the acute exposure group: patients with acute exposure to organophosphates, with the specified age limits * For the chronic exposure group: patients with chronic exposure to organophosphates, with the specified age limits No restrictions on comorbidities in the three groups except those mentioned under
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Identification of neuroinflammatory biomarker | 1.5 years | The biomarker should correlate with nerve injury |
| Identification of the mechanism of neuroinflammation | 1.5 years | To detect the possible pathways involved in initiation of systemic inflammation rather than inhibition of choline esterase enzyme. As well as, studying the possible relation of these identified mechanisms with neuronal inflammation and damage. |
Countries
Egypt
Contacts
Primary ContactAhmed F. El Yazbi, professor
Backup ContactDina M. El-Gameel, Bachelor of Clinical Pharmacy
Outcome results
None listed